The AGGF1 Knockout Ca Ski Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population derived from the Ca Ski human cervical carcinoma cell line, designed as a loss-of-function model for the angiogenic factor AGGF1. The polyclonal format ensures a heterogeneous array of gene-disrupted alleles, providing a robust tool for investigating AGGF1 function in an epithelial cancer context. This product enables studies of tumor angiogenesis, signal transduction, and cervical cancer biology without reliance on single-cell clonal isolates.
Ca Ski cells are a human cervical epidermoid carcinoma line harboring integrated human papillomavirus type 16 (HPV16) genomes, representing a relevant model for HPV-positive cervical cancer. They express viral oncoproteins E6 and E7, which disrupt tumor suppressors p53 and pRb, and maintain epithelial morphology. This cell line is widely used to study cervical cancer progression, drug responses, and the molecular mechanisms of viral oncogenesis.
AGGF1 functions as a potent angiogenic factor, promoting endothelial cell proliferation, migration, and tube formation through activation of the PI3K-AKT and ERK1/2 pathways. It couples upstream signals from hypoxia and TNF-alpha to downstream effectors including AKT, mTOR, ERK1/2, IKK, and NF-kB. AGGF1 physically interacts with TNFAIP3 (A20), RIPK1, and TRAF2, facilitating NF-kB activation by relieving A20-mediated inhibition of RIPK1. This leads to enhanced NF-kB transcriptional activity and increased expression of angiogenic targets such as VEGF, thereby driving vascular development and tumor angiogenesis.
In the Ca Ski cervical carcinoma model, AGGF1 knockout allows dissection of its role in HPV-driven malignancy. The loss of AGGF1 can alter the phosphorylation status of AKT and ERK1/2, diminish NF-kB signaling, and reduce VEGF production, potentially impairing paracrine angiogenic support to the tumor microenvironment. This model is instrumental for examining how angiogenic factors cooperate with viral oncoproteins to sustain cervical cancer cell survival, proliferation, and metastatic potential.
Typical research applications include investigation of AGGF1-dependent signaling in cervical cancer, screening of anti-angiogenic compounds, and functional studies of NF-kB and AKT/ERK pathway crosstalk. The polyclonal knockout cells are compatible with a range of assays: western blotting, RT-qPCR, tube formation assays, migration and invasion assays, phospho-specific ELISA for AKT and ERK1/2, cell proliferation assays, and drug sensitivity testing. For additional information or to discuss customized applications, please contact Ascent Research.
